GSK’s multiple myeloma drug, Blenrep, was withdrawn from the market but is now accumulating new clinical data that could support its return, potentially as an earlier line of therapy. The latest results from a Phase 3 study show that Blenrep helps patients live longer, with a 48% reduction in the risk of disease progression or death. Safety risks associated with the drug have been addressed through dose modifications to manage eye toxicity. Clinicians believe that Blenrep, with its immune response benefits, can meet the unmet need for novel combination therapies in the relapse setting. GSK is working to rebuild its case for Blenrep based on new clinical data.
Source link
GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO
